Artelo Biosciences, Inc. (NASDAQ:ARTL) Short Interest Up 9.2% in March

Artelo Biosciences, Inc. (NASDAQ:ARTLGet Free Report) was the recipient of a large growth in short interest in March. As of March 15th, there was short interest totalling 20,200 shares, a growth of 9.2% from the February 29th total of 18,500 shares. Currently, 0.6% of the shares of the stock are sold short. Based on an average daily volume of 18,100 shares, the days-to-cover ratio is presently 1.1 days.

Artelo Biosciences Price Performance

Shares of ARTL stock opened at $1.52 on Tuesday. Artelo Biosciences has a 1-year low of $1.15 and a 1-year high of $2.98. The business has a 50-day moving average of $1.49 and a 200 day moving average of $1.43. The stock has a market capitalization of $4.92 million, a PE ratio of -0.49 and a beta of 1.46.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Two Sigma Investments LP purchased a new position in shares of Artelo Biosciences in the 3rd quarter worth $37,000. Two Sigma Advisers LP bought a new position in shares of Artelo Biosciences in the third quarter worth about $121,000. Finally, Renaissance Technologies LLC lifted its position in shares of Artelo Biosciences by 67.8% in the first quarter. Renaissance Technologies LLC now owns 182,619 shares of the company’s stock worth $82,000 after buying an additional 73,819 shares in the last quarter. Institutional investors own 0.87% of the company’s stock.

About Artelo Biosciences

(Get Free Report)

Artelo Biosciences, Inc, a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for treating breast and prostate cancer, neuropathic and nociceptive pain, and anxiety disorders, including PTSD.

Featured Stories

Receive News & Ratings for Artelo Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artelo Biosciences and related companies with's FREE daily email newsletter.